Recent Company News

• 05:38 PM ET Jun 04, 2026
  

  Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma

• 10:08 AM ET Jun 04, 2026
  

  Supreme Court rules in Hikma Pharmaceuticals v. Amarin Pharma; reverses and remands Federal Circuit decision, holding that Amarin has failed to state a claim for active patent infringement

• 07:07 AM ET Jun 04, 2026
  

  Hikma Pharmaceuticals a publié son Rapport de durabilité 2025 (1441.0000p, +25)

• 07:07 AM ET Jun 04, 2026
  

  Hikma Pharmaceuticals published its 2025 Sustainability Report (1441.0000p, +25)

• 03:14 PM ET Jun 03, 2026
  

  Hikma Pharmaceuticals announces launch of Tofacitinib oral solution in US (1416.0000p, 0)

• 03:14 PM ET Jun 03, 2026
  

  Hikma Pharmaceuticals annonce le lancement de la solution buvable de tofacitinib aux États-Unis (1416.0000p, 0)

• 09:21 AM ET Jun 03, 2026
  

  StreetAccount Summary - This Term's Notable Supreme Court Cases

• 06:28 AM ET May 26, 2026
  

  Shanghai Junshi Biosciences meets primary endpoint in phase III clinical trial of Toripalimab for treatment of non-small cell lung cancer (HK$21.66, 0.00)

• 05:52 AM ET May 21, 2026
  

  NMPA approves marketing of Junshi Biosciences's JS001 to be combined with disitamab vedotin for urothelial carcinoma with HER2 expression (HK$23.86, 0.00)